Central Institute Of Mental Health, Mannheim
Clinical trials sponsored by Central Institute Of Mental Health, Mannheim, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Shock therapy maintenance may keep schizophrenia at bay Results expected Jul 2027 (estimated)
-
CBD shows promise for schizophrenia in new trial
Disease control OngoingThis phase II trial tests whether cannabidiol (CBD) capsules, added to standard antipsychotic medication, can help people with early schizophrenia recover better and stay on treatment longer. 180 participants receive either CBD or placebo for 26 weeks. The goal is to see if CBD i…
Phase 2 • Sponsor: Central Institute of Mental Health, Mannheim • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a 'Love Hormone' nasal spray help people with schizophrenia connect better?
Symptom relief OngoingThis phase 2 trial tests whether adding oxytocin nasal spray to standard psychosocial treatment can improve social skills and reduce symptoms in adults with schizophrenia spectrum disorders. Participants receive either oxytocin or a placebo spray alongside their usual therapy. Th…
Phase 2 • Sponsor: Central Institute of Mental Health, Mannheim • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC